To allow vaccination irrespective of HLA type. DNA vaccines encoding full-length antigens are required. However. here. we demonstrate that the immunogenicity of DNA vaccines encoding the full-length human papillomavirus (HPV) type 16 E7 and E6 proteins is highly reduced compared to vaccines encoding only the immunodominant epitope. Furthermore. the low remaining immunogenicity is essentially lost for both E7 and E6 when a nononcogenic "gene-shuffled" variant is utilized. To address these issues. we tested whether alterations in transgene design can restore the immunogenicity of full-length and geneshuffled DNA vaccines. Remarkably. genetic fusion of E7 with tetanus toxin fragment C (TIFC) resulted in a dramatic increase in immunogenicity both for the full-length and the gene-shuffled version of E7. Moreover. the nFC fusion vaccines were more immunogenic than a vaccine encoding a fusion of E7 and mycobacterial heat shock protein-70. which has recently been tested in a clinical trial. Interestingly. vaccination with these nFC fusion vaccines also resulted in extremely persistent T-cell responses. The E7-specific CD8+ T cells induced by nFC fusion vaccines were functional in terms of IFN-'Y production.
nation strategy named DNA tattoo vaccination that can potentially overcome this translational block. This strategy was shown to lead to the rapid induction of cellular immunity when compared to conventional methods of DNA vaccination in mice.
16 Furthermore. DNA tattooing outperformed classical intramuscular DNA vaccination by 10-to lOO-fold when tested in non-human primates. 17 Currently. DNA tattoo vaccination is being evaluated in a Phase I clinical trial for the treatment of melanoma, using a DNA vaccine that was produced in house in a GMP compliant plasmid production facility. IS In our current study. we describe the preclinical development of DNA vaccines directed against HPV 16 £6 and £7. aiming for optimal safety and immunogenicity. In earlier work. we have established that DNA vaccines that encode Single defined antigen-derived T-cell epitopes are highly immunogenic. 19 However, the extensive polymorphism of HLA alleles precludes the broader application of such epitopedirected DNA vaccines. and we therefore set out to develop effective DNA vaccines that encompass the full epitopeencoding potential of the HPV 16 E6 and E7 proteins. Furthermore, as HPV 16 E6 and E7 are oncogenes through their ability to induce degradation of the tumor suppressors p53 and pRb, respectively, 20," I the transforming potential of these genes needs to be eliminated before application in humans. Two strategies have previously been put forward to disrupt the oncogenic potential of E6 and E7 in DNA vaccines. First, point mutations in the pRb-binding site for E7 and in the p53-binding site for E6 can prevent degradation of these targets and thus prevent cellular transformation. I 1,22 Second, a more drastic approach-termed gene shuffling-has been developed recently to prevent the risk of cellular transformation by HPV 16 E7. 9 ,23 In this approach, the gene sequence of E7 was taken apart at exactly those positions that are critical for the known transforming properties of the protein, and the resulting fragments were reassembled in a "shuffled" order. To avoid the loss of putative CDS+ T-cell epitopes at the junctions, sequences encoding the nine amino acids at either side of the different junctions in the natural protein were added as an "appendix." As the three-dimensional structure of the resulting protein product will be markedly different from that of the parental protein, it is plausible that for thus shuffled proteins not only the binding to known cellular targets but also interaction with other potential targets20.2 1.24.25 is prevented. Consequently, gene shuffling can be considered a preferred approach from a safety perspective. Here, we demonstrate that the immunogenicity of DNA vaccines that encode the full-length HPV 16 E6 or E7 proteins is highly reduced when compared to vaccines in which only the immunodominant epitope is present. Furthermore, this low remaining immunogenicity is essentially lost when the preferred shuffled E6 and E7 vaccine formats are utilized. We subsequently demonstrate how DNA vaccines with a superior capacity for CDS + T-cell priming can be generated through the genetic fusion of either full-length or gene-shuffled HPV genes with domain 1 of tetanus toxin fragment C (TTFC). Collectively, these experiments define the transgene formats for HPV 16 E6 and E7 DNA vaccines for use in an upcoming Phase I clinical trial.
Material and Methods

Mice
C57BLl6 mice (6-10 weeks) were obtained from the experimental animal department of The Netherlands Cancer Institute (Amsterdam, The Netherlands) . All experiments were performed in accordance with institutional and national guidelines and were approved by the Experimental Animal Committee of The Netherlands Cancer Institute and in accordance with institutional and national guidelines.
DNA vaccines
DNA vaccines based on HPV 16 E6 and E7 genes were generated by the introduction of target genes or gene fragments into pVAX 1 (Invitrogen, Carlsbad, CA) . The generation of GFP-E7 49 _ 57 has been described e1sewhere.
2 (' GFP-E6 48 _ 57 encodes the immunodominant H-2K b -restricted epitope EVYDFAFRDL as a genetic fusion with GFP and was constructed in an analogous manner as GFP-E7 4 9 _ 57 , in between the Bam HI and Not I sites of pVAX. E7WT, E7GGG,11 E6WT and E6GG 22 were obtained from GeneArt (Hilden, Germany), with codon optimization for expression in human cells, and were all cloned between the HindIII and Xbal sites of pVAX. The generation of E7SH has been described elsewhere,23 and E6SH was constructed in a similar fashion . In brief, E6 was cut at positions corresponding to aa 31132, aa 64/65, aa 104/105 and aa 137/13S; the resulting five segments were reassembled in the order ADCBE, and the original junctions destroyed by the dissection were added as an "appendix." The design of E6SH is shown in Supporting Information Figure 1 . For our current study, both E6SH and E7SH were cloned between HindIII and XbaI sites of pV AX. The TTFC fusions, TTFC-E7WT, TTFC-E7GGG, TTFC-E7SH and TTFC-E6SH, were generated by C-terminal fusion of the gene of interest to TTFC domain 1 through PCR. All PCR products were cloned into the HindIII and XbaI sites of pVAX. pNGVL4a-sig/E7(detox)HSP70 15 was a kind gift from T.e. Wu. Sequences were confirmed by sequence analysis. Plasm ids were expressed and amplified in E. coli DH5ct and were purified using an endotoxin-free DNA purification kit (Qiagen, Hilden, Germany). DNA vaccines for intradermal tattoo application were dissolved in water for injections (Aqua B. Braun, Melsungen, Germany).
Tattoo vaccination
Intradermal DNA tattoo vaccination was performed at Day 0, 3 and 6, as described previously, with minor modifications. 16 One day before the first DNA tattoo, the hair on the hind leg was removed using depilating cream (Veet®, Reckitt Benckiser, Hull, UK). On the day of vaccination, mice were anesthetized, and 10 ~ll of a 2 ~lghll DNA solution in water was applied to the hairless skin of the hind leg. The DNA vaccine was applied with a Permanent Make Up tattoo machine (kindly provided by MT Denn GmbH, Berlin, Germany), using a sterile disposable nine-needle bar with a needle depth of 1 mm and oscillating at a frequency of 100 Hz for 30 sec. IFN-y assays were performed using the BD Cytofix/Cytoperm kit (Becton Dickinson Sciences. Franklin Lakes, NJ) according to the manufacturer's protocol. Peripheral blood cells were stimulated for 4 hr at a 1 I1g E7 49 -57 peptide (RAHYNIVTF) concentration and subsequently stained using PE-conjugated anti-INF-y mAb (BD Pharmingen, San Diego, CA) and APC-conjugated anti-CDSa mAb (BD Pharmingen). All samples were analyzed on a FACScalibur (Becton Dickinson) using Flow-Jo software (Three Star, Ashland, USA) for data analysis.
Detection of HPV-specific T cells in peripheral blood
In vivo cytotoxicity assay The capacity to kill peptide-loaded target cells in vivo was assayed as described previously.28 Briefly, splenocytes from naive mice were labeled with either 0.1 11M CFSE (low) or 1 11M CFSE (high). The cells labeled with 1 11M CFSE were subsequently pulsed with 10 11M RAHYNIVTF peptide for 1 hr at 37"C, and the cells labeled with 0.1 11M CFSE were pulsed with a control (influenza A-derived ASNENMDAM) peptide. After peptide loading, cells were washed three times and subsequently injected into mice in a 1:1 ratio for a total of 2 x 10 6 cells per mouse. After 20 hr, spleen cells were isolated, and the ratio of CFSEhigl/CFSElow cells was determined by flow cytometry. The percentage antigen-specific cytotoxicity was determined as follows: 100 -([% CFSE high in vaccinated/% CFSE low in vaccinated)/{% CFSE high in naive/% CFSE low in naive)] • 100).
TC·l tumor challenge C57BLl6 mice were injected subcutaneously with 1 x lOs TC-l tumor cells that express both HPV 16 E6 and E7. 29 DNA tattoo vaccination was subsequently performed on Day 3, 6 and 9 after tumor challenge. Tumor growth was monitored one to three times per week using caliper measurements in two dimensions. The volume of the tumors was calculated as follows: volume = {width 2 x length)/2. 3o Mice were sacrificed when the tumor diameter reached 15 mm or when the tumor volume exceeded 1,000 mm 3 . Statistical analysis Statistical analysis was performed using a Student's t-test. A p value < 0.05 was considered to be significant (two tailed). All findings were confirmed in at least one additional independent experiment. 
Results
Immunogenicity of HPV 16 E7 and E6 DNA vaccines is highly dependent on transgene design
We first compared the immunogenicity of the immunodominan t HPV 16 E7 49 -57 epitope wh en either present within the full-length E7 gene or as a C-terminal fusion of the single epitope with GFP (see Figs. la -I e (Fig. 1d) .
Taken together, these results demonstrate that the context in which a defined HPV 16 E7 or E6 CD8+ T-cell epitope is delivered strongly influences its immunogenicity. Importantly, the poor performance of the full -length or shuffled versions necessitated the optimization of the DNA vaccine design before moving to clinical evaluation.
Fusion of full-length E7 with TTFC domain 1 results in a dramatic Increase in COS+ T-cell responses
As CD8+ T-cell responses to the gene-shuffled DNA vaccines were essentially undetectable, we first focused on improving the immunogenicity of the wild-type and pointmutated versions, choosing HPV 16 E7 as a model vaccine. Prior work by Stevenson and coworkers has demonstrated that fusio n of antigenic peptides with the C-terminus of TTFC domain 1 (hereafter referred to as TTFC) enhances CD8;-T-cell responses against these peptides. 3 1 To evaluate whether this strategy would also be successful for the fulllength E7 protein, we generated DNA vaccines conSisting of C-terminal fusions of E7WT and E7GGG with TTFC (Fig.  2a) . Vaccination of mice with TTFC-E7WT and TTFC-E7GGG resulted in E7.j9_5T specific CD8+ T-cell responses that were markedly increased relative to those induced by E7WT, with mean peak CD8+ T-cell frequencies of 17.6% ± 9.83% and 16.6% ± 9.85%, respectively (Fig. 2b) . Importantly, the responses induced by the TTFC-fusion vaccines were also markedly higher than those induced by sig/ E7(detox)HSP (mean peak CD8 + T-cell frequencies of 5.79% ± 3. 15%), which has recently been tested in a clinical trial. ls Surprisingly, fusion to TTFC did not only increase the peak height of the CTL response but also caused a marked change in response kinetics. Specifically, although classical vaccine-induced cellular immune responses (as induced by all other vaccine formats tested) are characterized by a rapid contraction after the peak of the T-cell response, tattoo vaccination with TTFC-E7 DNA vaccines induced CD8+ T-cell responses that remained near constant for about 3 weeks after the peak of the CD8 + T-cell response was reached (Fig. 2b) . Furthermore, also in the months The mean percentage ± SO of H-20b E749_srspec ific COS+ T cells for the indicated groups is displayed over time.
following vaccination, marked DNA vaccine-induced T-cell responses remained detectable directly ex vivo .
Functional characterization of TIFC E7 induced long-term persisting cells
As the kinetics of the E7-specific CDS+ T-cell responses induced by TTFC-E7 vaccines were so markedly different from classical vaccine-induced CDS+ T-cell responses, we investigated the functional properties of these cells. First, the ability of CDS·!·· T cells to produce IFN-y upon E7 49 -57 peptide stimulation was tested by intracellular cytokine staining of peripheral blood samples taken from DNA tattoo-vaccinated mice (Fig.  3) . Four weeks after vaccination, the production of IFN-y could be detected in 4.4% ::' :: 3.03% and 3.6% ::' :: 1.14% of CDS+ T cells of TTFC-E7WT-and TTFC-E7GGG-vaccinated mice, respectively. In contrast, essentially no IFN-y production above background could be observed in samples taken from E7WT-and E7GGG-vaccinated mice. Second, the ability of the vaccination-induced T-cell pool to respond to secondary antigen encounter was evaluated by a single homologous booster vaccination 3 months after priming (Fig. 3c) . Peak secondary T-cell responses were comparable in size to the primary response for both TTFC-E7WT and TTFC-E7GGG. In contrast, in E7WT-and E7GGG-vaccinated mice, secondary T-cell responses were markedly reduced relative to the primary response. As a result, the differences between E7WT and TTFC-E7WT (7.7-fold; P < 0.05) and E7GGG and TTFC-E7GGG (l2.2-fold; P < 0.001)
were even more pronounced during the secondary response. As a third and final test for T-cell functionality of the longterm persisting HPV E7-specific CDS+ T cells, the ability to kill peptide-loaded target cells was tested in an in vivo cytolytic assay 6 weeks after priming with either TTFC-E7GGG or (Fig, 4) , In TTFC-E7GGG-vaccinated mice, 59.1% :': 13,7% specific lysis of target cells was observed compared to only 15.9% :': 4.3% in E7GGG-vaccinated mice (p = 0.0013), Taken together, these results demonstrate that DNA tattoo vaccination of mice with TTFC-E7 fusion vaccines induces superior T-cell reactivity compared to E7 vaccines as revealed by both antigen-specific T-cell numbers and their function .
TTFC fusion also enhances the immunogenicity of the E7SH and E6SH DNA vaccines
Because of the perceived greater safety of shuffled HPV 16 E6 and E7 genes when compared to point-mutated HPV 16 E6/E7 genes, we evaluated whether the immunogenicity of the very weakly immunogenic shuffled DNA vaccines could also be enhanced by TTCF fusion , As shown in Figure Sa , the use of TTFC-E7SH resulted in a strong E7-specific CDS-i-T-cell response with an 1L7-fold (p < 0,01) difference at the peak of the response compared to E7SH, Moreover, both the magnitude and persistence of the primary and secondary CDS+ T-cell response induced by TTFC-E7SH were comparable to that induced by vaccination with TTFC-E7WT. Evaluation of the magnitude of CDS + T-cell responses induced by TTFC-E6SH relative to those induced by E6SH (Fig. 5b) revealed a modest but nonsignificant increase in primary T-cell responses (3,0-fold; p = 0,27), The delayed contraction of the vaccination-induced immune response, observed for TTFC-E7 fusions, was not seen for TTFC-E6SH. However, following homologous boost vaccination, E6-specific CDS+ T-cell responses in TTFC-E6SH-vaccinated mice were markedly higher than those in E6SH-vaccinated mice (14.6-fold at the peak of the response, p < 0,01 
Comparing the antitumor effect of E7SH and TTFC·E7SH DNA vaccines
To evaluate whether the difference in immunogenicity resulting from the TTFC fusion translated into a measurable difference in the ability of vaccine-induced T cells to eradicate HPV 16 E6/E7-transformed tumors, mice were inoculated subcutaneously with 1 x 10 5 TC-} tumor cells. At Day 3 post-tumor cell injection, at which point most of the animals carry palpable tumors, tattoo vaccination with E7SH, TTFC-E7SH or a control DNA vaccine was initiated. In the animals treated with empty vector, E7 -specific T-cell responses remained below the level of detection indicating that the TC-1 tumor itself is not immunogenic (Fig. 6a) . Also, in animals treated with the E7SH DNA vaccine, E7-specific T-cell responses remained close to background, and tumor outgrowth and survival were indistinguishable between the two groups. In contrast, in animals treated with the TTFC-E7SH fusion vaccine, a robust E7-specific T-cell response emerged (26.7% ±: 20.6%) .
This T-cell response was accompanied by tumor regression and resulted in a prolonged survival for all mice (Figs. 6b and   6c ) . In spite of the high frequencies of E7-specific CDS " T cells in TTFC-E7SH-vaccinated mice, tumors did eventually recur in 60% of the mice, indicating that the TC-1 tumors can grow out in the face of an ongoing high-level E7-specific T-cell response. This immune evasion by TC-} tumors has been described previously and has been attributed to both mutation of the immunodominant epitope and increased expression of vascular cell adhesion molecule-} on the tumor cells. summary, the increased immunogenicity of the sh uffled E7 DNA vaccine obtained by TTFC fusion resulted in a highly reduced tumor outgrowth and a significant increase in median survival (p < 0.002; log-rank test).
Discussion
The aim of our study was to design safe and highly immunogenic DNA vaccines that encode the full-length HPV 16 E6 and E7 oncogenes. E6-and E7-encoding genetic vaccines thus far used in clinical trials contain point mutations that avoid binding of the encoded proteins to p53 and pRB, respectively. 7.3.' However, it is well recognized that both HPV 16 E6 and E7 also interact with other cellular targets than p53 and pRB, and that these interactions may play an additional role in cellular transformation. l,2o.1I .24.25.35 Because of this concern, the use of E6 and E7 vaccine formats in which the potential of E6 and E7 to interact with cellular targets is altered in a more drastic manner appears preferable. Therefore, we aimed to develop DNA vaccines that encode gene-shuffled variants of E6 and E7. Prior studies have already demonstrated the loss of oncogenic potential of the shuffled variant of E7 in in vitro assays.9.23 Likewise, sh uffled E6 shows a complete lack of transforming potential (Ohlschlager et ai., unpublished observations) .
Although shuffled E6 and E7 genes therefore appear suitable for use in genetic vaccines from a safety perspective, we here observed that the immunogenicity of E7SH and E6S H upon DNA tattoo is strongly reduced when compared to both the unmodified and the point-mutated variants of E6 and E7. How can the low immunogenicity of E6SH and E7SH be explained? A possible explanation for the reduced immunogenicity of these shuffled gene products is that these proteins are misfolded and hence rapidly degraded. Prior work has demonstrated that cross presentation of MHC class I-restricted epitopes is biased toward epitopes that accumulate in the antigen-producing cell,36.37 and induction of CDS '" T -cell responses upon DNA tattoo administration is known to depend at least partially on cross presentation. 38 In further support of this, we have previously demonstrated that in vivo antigen stability and immunogenicity of DNA vaccineencoded antigens that are introduced via intradermal DNA tattooing are correlated, and that the destabilization of a model vaccine via an approach very similar to gene shuffljng also resulted in the loss of vaccine immunogenicity.38 As a second potential explanation, the gene shuffling procedure could conceivably disrupt CD4+ T-cell epitopes present within the parental protein. However, as a deleterious effect of gene shuffljng is observed for both E6 and E7, and as the regions that encompass the sites at which the parental protein is taken apart are rescued in the "appendix," this explanation seems less likely. It has to be noted that the immunogenicity of (nonfused) E7SH and E7WT was comparable in a previous report. 23 Potentially, differences in the route of administration (intramuscular injection versus intradermal tattoo) or number of administrations (single injection versus three DNA tattoo applications) could influence the immunogenicity of shuffled DNA vaccines. Regardless of this, from the current analyses. it is apparent that for the planned clinical application, i.e., intradermal DNA taUoo, gene shuffling is highly detrimental to the immunogenicity of both HPV E6 and E7.
We and others have previously demonstrated that DNA vaccines can be improved by fusing genes encoding an antigen or an epitope of interest to that of a carrier protein?·8. ' 2. ' 9 Here, we demonstrate for both E6SH and E7SH that their immunogenicity can be fully remedied by genetic linkage to TTFC, priorly developed as a fusion partner in DNA vaccines by the group of Stevenson. 6 • 39 In these studies, the optimal configuration for the induction of CDS + T-cell immunity consisted of a C-terminal fusion of a minimal epitope with domain 1 of FrC {here referred to as TTFC for simplicity).6.31.4o Here, we show for the first time that th e beneficial effects of TTFC fusion do also apply to full-length gene products, thereby allowing antigen presentation via multiple HLA class I alleles. What is the mechanism by which fusion with a carrier molecule enhances DNA vaccine immunogenicity? In the case of TTFC, a likely explanation is that fusion of genes of interest to TTFC promotes the induction of CDS+ T-cell responses through the provision of CD4 + T-cell help via one of the TTFC-encoded "promiscuous" CD4+ helper epitopes. 6 • 39 Support for this notion comes from prior work demonstrating that a carrier protein needs to be of non-self-origin to improve DNA vaccine immunogenicity and that CDS+ T-cell responses toward a carrier-epitope fusion encoding DNA vaccine are dependent on MHC-II-mediated antigen presentation. 19 In line with this, MHC-II -/ --mice were not able to mount measurable CDS+ T-cell responses after vaccination with either TTFC-E6SH or TTFC E7SH (Supporting Information Fig. 2 ). However, it is plausible that the presence of helper T-cell epitopes is not the only relevant factor, as-as discussed above-antigen stability correlates with the immunogenicity of DNA vaccines. To assess whether TTFC fusion may increase the accumulation of E7{SH) protein, we transfected HEK293 cells with either E7WT or E7SH or with TTFC-E7WT or TTFC-E7SH and detected E7 protein expression by Western blot analysis 24 hr after transfection. As shown in Supporting Information Figure 3 , E7 accumulation was substantially higher in the TTFC E7{SH)-transfected cells, indicating that the stability of E7 is indeed improved by this fusion.
A remarkable observation in our study is the delayed contraction of the CDS+ T-cell responses upon DNA tattoo vaccination with all TTFC-E7 fusion vaccines tested. Conventional CDS + T-cell responses rapidly contract after the peak References 405 of the response has been reach ed, and levels of CD8 + T cells that remain after contraction are generally around 5% of peak levels. 4 1 • H In all our previous studies, immune responses induced by DNA tattoo showed similar kinetics, with contraction being close to complete about I week after the peak of the response.
16
• 38 In contrast, upon tattooing TTFC-E7-encoding DNA vaccines, we consistently observed that contraction of the induced CDS + T-cell response was delayed for about 3 weeks, and that the remaining frequencies after 4 weeks were still around 20% of the initial peak height (Fig.  3) . At present, we do not know the cause of this delayed contraction, but the data available suggest that a combination of epitope-intrinsic and epitope-extrinsic factors is required. Specifically, the fact that delayed contraction is observed for TTFC-E7 but not for TTFC-E6 DNA vaccines indicates that epitope identity does playa role. On the other hand, the fact that delayed contraction is observed for TTFC-E7 but not for GFP-E7 49 _ S7 DNA vaccines shows that the identity of the carrier also forms a crucial component. Clearly, understanding the molecular basis underlying both the increase in peak height and the improved persistence of CD8""' T-cell responses induced by these fusion vaccines would be highly useful for future DNA vaccine development and will be the focus of our future work.
In conclusion, we have constructed DNA vaccines targeting full -length HPV 16 E6 and E7 with good immunogenicity and safety profiles, by successfully combining strategies to "detoxify" and improve DNA vaccine-encoded antigens. The resulting vaccine format outperformed a vaccine encoding sig/E7{detox)HSP that was recently tested in humans,1 5 providing a strong rationale for clinical evaluation of our vaccine format. We are currently planning to evaluate a combination of TTFC-E7SH-and TTFC-E6SH-encoding constructs, applied via DNA tattoo vaccination, for treatment of HPV 16-positive carcinomas in a Phase I clinical trial.
